Guggenheim Initiates Coverage On Verve Therapeutics with Buy Rating, Raises Price Target to $84
Guggenheim analyst Etzer Darout initiates coverage on Verve Therapeutics (NASDAQ:VERV) with a Buy rating and raises Price Target to $84.
JP Morgan Initiates Coverage On Verve Therapeutics with Neutral Rating, Announces Price Target of $50
JP Morgan analyst Eric Joseph initiates coverage on Verve Therapeutics (NASDAQ:VERV) with a Neutral rating and announces Price Target of $50.
Jefferies Initiates Coverage On Verve Therapeutics with Buy Rating
Jefferies analyst Eun Yang initiates coverage on Verve Therapeutics (NASDAQ:VERV) with a Buy rating.
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow.
58 Biggest Movers From Yesterday
Gainers
The Glimpse Group, Inc. (NASDAQ: VRAR) shares jumped 152.3% to settle at $17.66 on Thursday after the company priced its IPO at $7 per share.
72 Biggest Movers From Yesterday
Gainers
Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 405% to close at $30.30 on Wednesday after the company priced its IPO at $6 per share.
Stocks That Hit 52-Week Highs On Wednesday
This morning 132 companies reached new 52-week highs.
The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 29)